In patients with non-small-cell lung cancer, Domènech et al. demonstrated that those with MET amplification had a higher proportion of programmed death-ligand 1 (PD-L1) expression and overexpression than those with non-amplified MET [33]. Here, MET is linked to non-small cell lung carcinoma.